Regentis Biomaterials RGNT
NYSE RGNT
$2.10 +0.04 (+1.94%)
At close: Aug 21, 2026 · 4:00 PM EDT

Regentis Biomaterials (RGNT) Accumulated Expenses (2024 - 2025)

Regentis Biomaterials (RGNT) posted quarterly Accumulated Expenses of $1.4 million for Q4 2025, up 34725.0% year-over-year from N/an in Q4 2024, and up 34725.0% quarter-over-quarter from $4000.0 in Q4 2024.

Regentis Biomaterials (RGNT) Accumulated Expenses (2024 - 2025) Analysis & Trends

Regentis Biomaterials (RGNT) has reported Accumulated Expenses for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Accumulated Expenses rose 34725.0% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (up 34725.0% YoY), while the FY2025 annual figure was $1.4 million, up 34725.0% from the prior year.
  • Accumulated Expenses advanced to $1.4 million in Q4 2025 per RGNT's latest filing, from $4000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.4 million in Q4 2025 and bottomed at $4000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 134.13 Bn 128.91 Bn 1.96 Bn
2 Becton Dickinson 52.76 Bn 51.90 Bn 2.32 Bn
3 Alcon 35.81 Bn 34.46 Bn 1.68 Bn
4 Resmed 33.72 Bn 32.25 Bn 861.22 Mn
5 Medline 29.38 Bn 26.70 Bn 2.22 Bn
6 West Pharmaceutical Services 25.00 Bn 24.57 Bn 329.20 Mn
7 Solventum 15.46 Bn 15.06 Bn 1.29 Bn
8 Cooper Companies 14.88 Bn 14.74 Bn 735.40 Mn
9 Baxter International 13.58 Bn 11.43 Bn 1.03 Bn
10 Regentis Biomaterials 1.21 Mn -6.17 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.39 Mn
Dec 31, 2024 4,000.00